Approval · Notice of Compliance 763 · 2002
SYNAGIS: Notice of Compliance 763
Issued May 15, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 763
- Date
- May 15, 2002
- Company
- Abbott Laboratories Co.Saint-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Passive immunizing agent (humanized monoclonal antibody)
Products in this notice
Medicinal ingredients
- PALIVIZUMAB 100 MG per VIAL
- PALIVIZUMAB 50 MG per VIAL